These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17880451)

  • 41. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
    Manco-Johnson M
    Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia.
    Rentz A; Flood E; Altisent C; Bullinger M; Klamroth R; Garrido RP; Scharrer I; Schramm W; Gorina E;
    Haemophilia; 2008 Sep; 14(5):1023-34. PubMed ID: 18665853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
    Giangrande PL; Wilde JT; Madan B; Ludlam CA; Tuddenham EG; Goddard NJ; Dolan G; Ingerslev J
    Haemophilia; 2009 Mar; 15(2):501-8. PubMed ID: 19187194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy.
    Mauser-Bunschoten EP; Fransen Van De Putte DE; Schutgens RE
    Haemophilia; 2009 Jul; 15(4):853-63. PubMed ID: 19228203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An outline of the current orthopaedic management of haemophilic disease of the upper limb.
    Choudhury MZ; Mann HA; Goddard NJ; Lee CA
    Haemophilia; 2007 Sep; 13(5):599-605. PubMed ID: 17880450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe and moderate haemophilia A and B in US females.
    Di Michele DM; Gibb C; Lefkowitz JM; Ni Q; Gerber LM; Ganguly A
    Haemophilia; 2014 Mar; 20(2):e136-43. PubMed ID: 24533955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.
    van Dijk K; Fischer K; van der Bom JG; Grobbee DE; van den Berg HM
    Haemophilia; 2005 Sep; 11(5):438-43. PubMed ID: 16128885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr.
    Molho P; Rolland N; Lebrun T; Dirat G; Courpied JP; Croughs T; Duprat I; Sultan Y
    Haemophilia; 2000 Jan; 6(1):23-32. PubMed ID: 10632738
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
    Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
    Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life and sports activities in patients with haemophilia.
    VON Mackensen S
    Haemophilia; 2007 Sep; 13 Suppl 2():38-43. PubMed ID: 17685923
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic risk factors for inhibitors to factors VIII and IX.
    Oldenburg J; Pavlova A
    Haemophilia; 2006 Dec; 12 Suppl 6():15-22. PubMed ID: 17123389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pain and functional limitations in patients with severe haemophilia.
    van Genderen FR; Fischer K; Heijnen L; de Kleijn P; van den Berg HM; Helders PJ; van Meeteren NL
    Haemophilia; 2006 Mar; 12(2):147-53. PubMed ID: 16476089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice.
    Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Planchais C; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2015 Jan; 21(1):e94-8. PubMed ID: 25471131
    [No Abstract]   [Full Text] [Related]  

  • 58. Prophylaxis and treatment of chronic synovitis in haemophilia patients with inhibitors.
    Rodriguez-Merchan EC; Valentino L; Quintana M
    Haemophilia; 2007 Nov; 13 Suppl 3():45-8. PubMed ID: 17822521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Feasibility, safety and cost-effectiveness of transjugular liver biopsy following major surgery in patients with haemophilia.
    Detrait M; Pothen D; Brenard R; Starkel P; Hermans C
    Haemophilia; 2007 Sep; 13(5):588-92. PubMed ID: 17880448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.